Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H6L2

UPID:
TM231_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9H6L2; A0JLU1; A6NDZ6; B3KU85; G5E9E3; Q6P450; Q6UWW5

BACKGROUND:
The Transmembrane protein 231 is integral to the tectonic-like complex at primary cilia transition zones, acting as a barrier to protein diffusion and facilitating ciliogenesis and SHH signaling. Its role underscores the importance of cilia in cellular and developmental processes.

THERAPEUTIC SIGNIFICANCE:
Linked to Joubert syndrome 20 and Meckel syndrome 11, Transmembrane protein 231's dysfunction highlights its potential as a therapeutic target. Exploring its mechanisms could lead to novel treatments for these genetic disorders, emphasizing the therapeutic significance of this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.